MRD detection techniques in AML: pros and cons
Minimal residual disease (MRD) is a highly important prognostic indicator used to determine treatment efficacy in acute myeloid leukemia (AML) patients. Here, Chrisoph Rllig, MD, from the University ...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Managing relapse in AML: the role of MRD
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood counts or examining the morphology of the bone marrow is not suf...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapies for the treatment of AML
Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeutic agents, and the development of ...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Applying the right therapies to the right AML patient population
Chrisoph Rllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses how his team is carrying out treatment optimization trials to match established acute myeloid leukemia ...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Combination therapy for the treatment of AML
Chrisoph Rllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains how the lack of novel drugs for the treatment of acute myeloid leukemia (AML) in the past 50 years has l...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Increasing the effectiveness of ALL therapies
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Ho...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Minimal residual disease: a key determinant of ALL treatment response
Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker in predicting patient outcomes. MRD can aid in tailoring therapies a...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Improving response to ALL therapies
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses the novel and interesting approaches for first-line therapy, in acute lymphoblastic leukemia...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Challenges with the identification of ALL subtypes
Finding the right treatment for a specific subset of acute lymphoblastic leukemia (ALL) requires a correct diagnosis, but there are many challenges that clinicians face when trying to implement precis...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Overcoming the issues with clinical trial recruitment
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the importance of collaborating with other trial groups that are focusing on acute leukemias by joining efforts with o...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Midostaurin: the first drug to receive approval for AML since 2000
Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In this interview, Arnold Ganser, MD, from the Hannover Medical School, Hanno...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Finding the right targets for CAR T-cell therapy in AML
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, expla...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
The devastating effects of relapsed or refractory AML
Dealing with patients with refractory acute myeloid leukemia (AML) or with those who have relapsed, is challenging, and stem cell transplantation is one of the few therapies that can be offered in the...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany talks about his experience of the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest,...
Author: VJHemOnc
Added: 05/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Increasing AML clinical trial participation rates
Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the disease, standard treatment options for AML patients have not expe...
Author: VJOncology
Added: 05/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 25, 2018 Category: Cancer & Oncology Source Type: podcasts
